Compare XNCR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNCR | EVO |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 895.8M |
| IPO Year | 2013 | N/A |
| Metric | XNCR | EVO |
|---|---|---|
| Price | $11.57 | $2.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $22.33 | $7.00 |
| AVG Volume (30 Days) | ★ 814.8K | 110.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.88 | $7.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $2.31 |
| 52 Week High | $18.69 | $4.80 |
| Indicator | XNCR | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 32.84 |
| Support Level | $10.92 | $2.31 |
| Resistance Level | $12.87 | $3.75 |
| Average True Range (ATR) | 0.70 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 30.65 | 21.76 |
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.